Search Videos and More
National and International Accolades
Meet the bold clinicians and researchers whose work and perseverance push the edge of discovery, and have helped Fox Chase Cancer Center reach our 50th anniversary of excellence in cancer care.2024 Atlantic Regional Hematopathology Meeting
Advancements in hematopathology based on molecular and genetic information are rapidly evolving, making it challenging to keep up with the latest developments and their implications for diagnosis and therapy. This meeting will focus on the role of molecular pathology and new technologies in diagnosis, prognostic stratification, and treatment of complex cases. Participants will gain insights into the significant changes, revisions, and new categories in the 5th Edition of the World Health Organization Classification of Hematolymphoid Tumors. Renowned invited pathologists and senior authors of the new WHO edition, Dr. Joseph Khoury, Dr. German Ott, and Dr. Sanam Loghavi, will discuss notable updates, modifications, and new classifications in the morphology and molecular genetics of hematologic neoplasms that can be immediately applied in practice.Benign Prostatic Hyperplasia
With one of the largest and most experienced urology teams in the region and the latest treatment capabilities, the Fox Chase-Temple Urologic Institute is a trusted leader in treating all types of urologic conditions.Fox Chase-Temple Urologic Institute: The Next Generation of Urology Care
Our innovative partnership unites the expertise of distinguished institutions within one health system, allowing us to tackle the most challenging genitourinary malignancies as well as complex benign urologic conditions.Fox Chase Welcomes Leukemia Specialist Sara Small, MD, PhD
Sara Small, MD, PhD, assistant professor in the Department of Bone Marrow Transplant and Cellular Therapies.TAS1440 +/- All-Trans Retinoic Acid (ATRA) in Relapsed/Refractory AML
A first of its kind, Phase 1 multi-center study for Relapsed or Refractory Acute Myeloid Leukemia using an investigational drug TAS1440 by itself, and in combination with All-Trans Retinoic Acid (ATRA).Key Takeaways from 2023 American Society of Hematology Meeting
Fox Chase Physician Demonstrates Safety and Effectiveness of Myeloma Drug for Black or African American PatientsCelebrating 35 years of the Fox Chase-Temple University Hospital Bone Marrow Transplant Program
One of the truly gratifying truths about cancer care is the amazing progress we have made in just the last few decades.Optimizing Treatment Strategies for Localized and Advanced Genitourinary Malignancies
This educational program, offered by Fox Chase Cancer Center and the Temple Health Office for Continuing Medical Education. The program will cover the latest strategies for optimally managing localized and advanced bladder, kidney, and prostate cancer and is presented by the Fox Chase Cancer Center genitourinary oncology team—nationally recognized physicians specializing in urology, radiation therapy, and medical oncology.A New Fellowship For Breast Imaging Leadership
The new fellow will spend nine months on interpreting, screening, and diagnostic procedures, learn how to perform all forms of biopsies using the most advanced techniques; and gain skills to run a breast imaging center.Profile UNC: Dr. Karyn Stitzenberg
For some, cancer is not the worst challenge.New Medical Oncology Leadership Advances Clinical Care, Research, Discovery, and Delivery at Temple Health and Fox Chase
For Fox Chase Cancer Center and the larger Temple Health community, the appointment of Martin Edelman, MD, is an exciting new opportunity to collaborate and integrate cancer care within these two institutions.